Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses
Century Therapeutics (NASDAQ:IPSC) said abstracts for CNTY-813 were accepted for oral presentations at the 62nd EASD meeting (Sep 28-Oct 2, 2026, Milan) and the Breakthrough T1D Congress (Oct 9-11, 2026, Philadelphia). The iPSC-derived islet therapy uses Allo-Evasion 5.0. Company targets an IND submission in Q4 2026 and expects initial clinical data in H2 2027, citing June preclinical results.
How this was made
The 30-second read
Why it matters
The new information is primarily logistical (oral presentation acceptance) plus reiteration of IND timing and expected initial clinical data window, which can support sentiment but does not change the clinical evidence base in this article.
Market read
For IPSC, the article provides a near-term visibility boost via oral presentation acceptance and reiterates IND and clinical timing, but it does not introduce new efficacy/safety results.
What to watch
Key near-term risk is execution toward the Q4 2026 IND submission; any delay or adverse preclinical/regulatory feedback would outweigh conference scheduling.
Background
Century Therapeutics is developing CNTY-813, an iPSC-derived islet replacement therapy engineered with Allo-Evasion 5.0 for type 1 diabetes.
Ticker impact
Century Therapeutics said abstracts were accepted for oral presentations highlighting CNTY-813, with IND targeting in Q4 2026 and initial clinical data in H2 2027.
Likely limited, sentiment-driven reaction; bigger moves would require new efficacy/safety results or an IND filing update.
The article adds scheduling and reiterates previously stated development timelines, plus references prior preclinical data from June 9 without new results in this text.
Market effects
Reinforces ongoing investor focus on iPSC-derived islet replacement and immune-evasion approaches in type 1 diabetes cell therapy.
No direct regional market linkage beyond general US biotech sentiment.
European and US congress calendars may draw incremental attention from global T1D and cell-therapy investors.
Counterpoint
Abstract acceptance may reflect planned dissemination rather than new evidence, so the market may already be pricing the program timeline.
Key entities
- companyCentury Therapeutics, Inc.
NASDAQ-listed developer of allogeneic cell therapies; subject of the article.
- programCNTY-813
iPSC-derived islet replacement therapy program engineered with Allo-Evasion 5.0.
- technologyAllo-Evasion 5.0
Engineered immune-evasion approach referenced for CNTY-813.
- conference62nd Annual Meeting of the European Association for the Study of Diabetes
European congress scheduled Sep 28 to Oct 2, 2026 in Milan where CNTY-813 abstracts will be presented.
- conferenceBreakthrough T1D Clinical & Research Congress 2026
US congress scheduled Oct 9 to 11, 2026 in Philadelphia where CNTY-813 abstracts will be presented.
